Bloomington, Minn, September 11, 2009 – ImmunoChemistry Technologies, LLC, announced today that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has approved funding for Phase II of a fast track Phase I/II Small Business Innovation Research (SBIR) Grant, first awarded to the Company in September 2008. The award of over $640,000 is the second installment of the combined $850,000 grant to develop and test new reagents (FLIVO™) for fluorescence imaging of apoptotic tissues in various animal models of anti-cancer therapy. The work will be done in collaboration with the University of Minnesota.
Read more about our research and FLIVO™ on our website.
No comments:
Post a Comment